Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Opyl Ltd. ( (AU:OPL) ) is now available.
Opyl Ltd has signed a definitive Services Agreement with UK-based Innovatrix Capital Ltd, positioning its AI platform, TrialKey, as the exclusive Calculation Agent for Innovatrix’s clinical trial failure insurance products. This agreement not only validates TrialKey’s AI capabilities in a high-value application but also enhances Opyl’s global commercial reach, providing access to valuable clinical trial data and a user feedback loop to improve predictive accuracy. The partnership is expected to open new opportunities in AI-powered drug discovery and repurposing, placing TrialKey at the center of a global risk-transfer solution aimed at reducing trial failures and improving outcomes in the life sciences industry.
More about Opyl Ltd.
Opyl Ltd is a leader in AI-driven clinical trial optimization, focusing on enhancing the success rates of clinical trials through its proprietary AI platform, TrialKey. The company operates in the life sciences sector, providing AI solutions to improve clinical trial outcomes and reduce failure rates.
Average Trading Volume: 1,092,332
Technical Sentiment Signal: Sell
Current Market Cap: A$5.16M
Learn more about OPL stock on TipRanks’ Stock Analysis page.